polycystic kidney disease

polycystic kidney disease is a genetic disorder characterized by the progressive development of multiple fluid-filled renal cysts leading to enlarged kidneys and impaired renal function. It manifests across a spectrum from neonatal or childhood presentations to adult-onset disease and intersects with multiple medical, surgical, and public health domains. Historical descriptions and modern management involve contributions from clinicians, researchers, and institutions across nephrology.

Signs and symptoms

Patients commonly present with flank pain, palpable abdominal masses, and hematuria, often accompanied by hypertension and progressive reduction in urine concentrating ability. Progressive cyst expansion may cause recurrent urinary tract infections and nephrolithiasis, and extrarenal features can include hepatic cysts and intracranial aneurysms that carry risks of subarachnoid hemorrhage; screening decisions often involve multidisciplinary input from neurosurgeons, vascular physicians, and radiologists. Symptoms may be precipitated by cyst hemorrhage or infection, and systemic manifestations such as left ventricular hypertrophy and valvular disease can require cardiology assessment.

Causes and pathophysiology

Inherited mutations in genes encoding ciliary proteins underlie most cases, altering tubular epithelial cell polarity, proliferation, and fluid secretion and perturbing intracellular calcium and cyclic AMP signaling pathways. Autosomal dominant forms frequently involve mutations in PKD1 and PKD2, while autosomal recessive disease is associated with PKHD1; genotype–phenotype correlations inform prognosis and family counseling with contributions from genetics clinics and molecular laboratories. Cellular mechanisms implicate primary cilia dysfunction that intersects with research from developmental biology groups, translational teams at university medical centers, and pharmaceutical research into targeted modulators of signaling axes such as mTOR and vasopressin V2 receptors.

Diagnosis

Diagnosis integrates imaging, genetic testing, and clinical criteria. Renal ultrasound is often the first-line modality used in outpatient clinics and emergency departments, with CT and MRI providing higher resolution for cyst characterization and preoperative planning; interpretation may involve radiology departments at academic hospitals and specialist radiologists. Genetic testing for PKD1, PKD2, and other relevant loci is available through clinical genetics services and commercial laboratories and is used for family planning and living donor evaluation. Diagnostic pathways also involve nephrology assessment, urinalysis, and measurement of renal function via serum creatinine and estimated glomerular filtration rate, often coordinated through tertiary referral centers.

Management and treatment

Management combines blood pressure control, infection management, and interventions to preserve renal function and address complications. Antihypertensive therapy—often guided by nephrologists and primary care physicians—frequently includes renin–angiotensin system blockers; disease-modifying pharmacotherapy such as vasopressin V2 receptor antagonists has emerged from clinical trials led by academic consortia and pharmaceutical companies. Supportive measures include pain management coordinated with anesthesiology and pain clinics, percutaneous drainage or cyst sclerotherapy performed by interventional radiologists, and surgical options including nephrectomy and renal replacement therapies delivered by transplant centers. End-stage renal disease is managed with dialysis modalities provided by dialysis networks and renal transplantation from living or deceased donors, with outcomes tracked by transplant registries and transplant surgeons. Reproductive counseling, prenatal diagnosis, and preimplantation genetic diagnosis involve reproductive endocrinology and genetics units.

Complications and prognosis

Complications include progressive chronic kidney disease leading to end-stage renal disease, recurrent infections, nephrolithiasis, cyst hemorrhage, hepatic cyst burden, and cardiovascular events such as heart failure and intracranial aneurysm rupture. Prognosis depends on genotype, total kidney volume trajectories assessed in longitudinal cohort studies, and comorbidities managed by multidisciplinary teams including cardiology and hepatology services. Long-term outcomes and health service planning are informed by population health studies, national renal registries, and guidelines from professional societies, with ongoing research from academic medical centers and collaborative networks aiming to improve disease-modifying therapies and patient-centered care.

Category:Kidney diseases